• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型 2 型糖尿病治疗药物 第 1 部分 - 注射用胰岛素。

New Injectable Agents for the Treatment of Type 2 Diabetes Part 1 - Injectable Insulins.

机构信息

Department of Clinical Pharmacy, University of Tennessee Health Science Center, Memphis; Department of Family Medicine, University of Tennessee Health Science Center, Memphis.

Department of Clinical Pharmacy, University of Tennessee Health Science Center, Memphis.

出版信息

Am J Med. 2018 Jul;131(7):752-754. doi: 10.1016/j.amjmed.2018.01.049. Epub 2018 Feb 26.

DOI:10.1016/j.amjmed.2018.01.049
PMID:29496503
Abstract

The United States Food and Drug Administration has recently approved several new insulin products and new formulations of existing insulin products. These new products may provide advantages over older products, such as a lower risk of nocturnal hypoglycemia and ease of dosing; however, they are costly. The first of 2 articles in a series, this review will describe the potential advantages and disadvantages of these new insulin products.

摘要

美国食品和药物管理局最近批准了几种新的胰岛素产品和现有胰岛素产品的新配方。这些新产品可能比旧产品具有优势,例如夜间低血糖风险较低和剂量方便;然而,它们价格昂贵。这是一系列文章中的第一篇,本篇综述将描述这些新胰岛素产品的潜在优缺点。

相似文献

1
New Injectable Agents for the Treatment of Type 2 Diabetes Part 1 - Injectable Insulins.新型 2 型糖尿病治疗药物 第 1 部分 - 注射用胰岛素。
Am J Med. 2018 Jul;131(7):752-754. doi: 10.1016/j.amjmed.2018.01.049. Epub 2018 Feb 26.
2
Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised?糖尿病的胰岛素治疗:如何最谨慎、有效地使用目前可用的注射用胰岛素?
Drugs. 2007;67(13):1813-27. doi: 10.2165/00003495-200767130-00002.
3
[Long-acting insulin analogs: progressing slowly].[长效胰岛素类似物:进展缓慢]
Ned Tijdschr Geneeskd. 2004 Aug 21;148(34):1668-9.
4
Update in the pharmacologic treatment of diabetes: focus on insulin detemir, insulin glulisine, and inhaled dry powdered insulin.糖尿病药物治疗的最新进展:聚焦于地特胰岛素、门冬胰岛素和吸入型干粉胰岛素。
Diabetes Educ. 2007 Mar-Apr;33(2):215-6, 220, 223-4 passim. doi: 10.1177/0145721707299264.
5
Long-acting insulin analogs.长效胰岛素类似物
Diabetes Care. 1999 Mar;22 Suppl 2:B109-13.
6
Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus.胰岛素与口服药物联合治疗:优化2型糖尿病患者的血糖控制
Diabetes Metab Res Rev. 2002 Sep-Oct;18 Suppl 3:S77-81. doi: 10.1002/dmrr.304.
7
Insulin lispro: a pharmacoeconomic review of its use in diabetes mellitus.赖脯胰岛素:其在糖尿病治疗中应用的药物经济学综述
Pharmacoeconomics. 2002;20(14):989-1025. doi: 10.2165/00019053-200220140-00004.
8
Determining effective insulin analog therapy based on the individualized needs of patients with type 2 diabetes mellitus.根据2型糖尿病患者的个体化需求确定有效的胰岛素类似物治疗方案。
Pharmacotherapy. 2008 Oct;28(10):1299-308. doi: 10.1592/phco.28.10.1299.
9
Insulin detemir: a new basal insulin analogue.地特胰岛素:一种新型基础胰岛素类似物。
Diabetes Obes Metab. 2006 Jan;8(1):26-30. doi: 10.1111/j.1463-1326.2005.00487.x.
10
2008 resource guide. Insulin. Along with human insulin analogs, recombinant DNA human insulins are the most widely used insulins in this country. Through genetic engineering, bacteria or yeast are transformed into little "factories" that produce synthetic human insulin.2008年资源指南。胰岛素。与胰岛素类似物一样,重组DNA人胰岛素是该国使用最广泛的胰岛素。通过基因工程,细菌或酵母被转化为生产合成人胰岛素的小型“工厂”。
Diabetes Forecast. 2008 Jan;61(1):RG11-4.

引用本文的文献

1
Suitable Use of Injectable Agents to Overcome Hypoglycemia Risk, Barriers, and Clinical Inertia in Community-Dwelling Older Adults with Type 2 Diabetes Mellitus.适用于克服社区居住的 2 型糖尿病老年患者低血糖风险、障碍和临床惰性的注射用药物。
Drugs Aging. 2019 Dec;36(12):1083-1096. doi: 10.1007/s40266-019-00706-4.
2
Tolerogenic Dendritic Cells and T-Regulatory Cells at the Clinical Trials Crossroad for the Treatment of Autoimmune Disease; Emphasis on Type 1 Diabetes Therapy.免疫耐受树突状细胞和调节性 T 细胞在治疗自身免疫性疾病的临床试验十字路口;重点是 1 型糖尿病治疗。
Front Immunol. 2019 Feb 6;10:148. doi: 10.3389/fimmu.2019.00148. eCollection 2019.